Navigation Links
Biomoda President Testifies Before New Mexico Legislature Supporting Clinical Funding for Early Lung Cancer
Date:10/2/2007

SANTA FE, N.M., Oct. 2 /PRNewswire-FirstCall/ -- John Cousins, President of Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, testified Monday before the New Mexico State Legislature's Interim Tobacco Settlement Committee in support of the lawmakers' $1.3 million proposal for funding a clinical study using the company's assay for early lung cancer detection.

The New Mexico legislature last year appropriated $350,000 to fund a clinical study that will begin later this year to screen veterans for lung cancer at its earliest stages. If approved, the $1.3 million funding proposal for 2008 would be a continuation of existing funding for the clinical study and will be considered during the state's 30-day legislative session beginning January 15, 2008.

"Members of the Tobacco Settlement Committee are at the forefront of funding essential studies to develop a nationwide screening protocol for lung cancer that ultimately will result in saving millions of lives," said Cousins. "We look forward to being part of this breakthrough effort and we are thrilled to be helping our veterans in this process. The men and women who served our country deserve the very best healthcare. This clinical work will provide just that."

Doug Craft, President of the Black Veterans Association of New Mexico, testified in support of Biomoda's efforts. "We are grateful for this opportunity and plan to work very hard to let our brothers and sisters who served in the military learn about, and be part of, this important opportunity that not only will further essential research, but also save lives."

Biomoda's technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope. The patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.

Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.

Contact: John Cousins (505) 821-0875


'/>"/>
SOURCE Biomoda, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Clintons new problem - Is the outgoing American president suffering from skin cancer?
2. Past President Narayanans Condition Still Critical
3. President and Founder of National Obesity Forum Resigns
4. President Bush Urges Citizens to Invest In Health Savings Account (HSAs)
5. President Bush proposes HSAs scheme for the benefit of both the workers and the country
6. President’s verdict: no need to panic over bird fl
7. Delhi Hospitals On Standby For President Bush
8. Former IMO President Shows Interest In Winning General Election
9. Chicken Dishes Were Off The Menu At Pakistan Presidents House
10. Man Appeals to President to Save His Ailing Son
11. President Kalam Meets Striking Medicos However Stir to Continue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Evoke ... young adults, has kicked off its 4th annual Forum for Innovative Treatment Solutions ... is “Attachment Informed Therapy for Mental Health and Addiction.” , FITS’ 2017 ...
(Date:4/21/2017)... ... 2017 , ... The adage “Show, don’t tell” applies perfectly to Green Builder ... esteemed VISION House demonstration project series. Manifesting the concept of right-sized living, the Flex ... to live affordably and abundantly without unduly taxing the resources of our beautiful planet. ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... with O2X , an active lifestyle company that provides Human Performance Training ... of firefighters, police offers, first responders, military officers and others in service through ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... held the much anticipated Regional Primary Care Spring Symposium on April 1, 2017 ... local medical community, offering physicians and healthcare providers an opportunity to learn about ...
(Date:4/21/2017)... City, UT (PRWEB) , ... April 21, 2017 , ... ... solutions, recently partnered with Advanced Patient Care of Utah (APCUT) and has appointed Rex ... for the next chapter of growth for our agency and our ability to provide ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research ... America Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, ... Segment Forecasts, 2014 - 2025" report to their offering. ... The Latin American ... 21.0 billion by 2025 Low drug registration cost ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
Breaking Medicine Technology: